A new paper in European Urology has suggested that men with localized prostate cancer who are treated by focal forms of high-intensity focused ultrasound (HIFU) have “a return to baseline International Index of Erectile Function — erectile and total International Index of Erectile Function scores” by 6 months after treatment which was maintained at 1 […]
Your sitemaster is pleased to be able to report a forthright and interesting discussion yesterday with Dr. Stephen Scionti about the current and future potential of high-intensity focused ultrasound (HIFU) in the treatment of prostate cancer.
Dr. Stephen Scionti is almost certainly the most experienced practitioner of high-intensity focused ultrasound (HIFU) as a first-line treatment for prostate cancer practicing in the USA today — although he has had to actually treat the vast majority of his patients outside of the USA.
As predicted in yesterday’s post about the nature of the approval of SonaCare Medical’s Sonablate technology as a “generic” form of treatment for prostate tissue ablation, we are likely to see rapid approval of the Ablatherm brand of HIFU technology here in America very soon as well.
According to a media release issued by SonaCare Medical early this morning, the company has received approval from the U.S. Food and Drug Administration (FDA) to market its Sonablate® 450 technology in the U.S.A. for prostate tissue ablation.
Readers may wish to be aware that your sitemaster has been hearing whispers and rumblings that the U.S. Food and Drug Administration is either about to or has just approved some form of Sonacare Medical’s Sonablate high-intensity focal ultrasound (HIFU) techology for treatment of something related to the prostate.
The chances that we will ever see a large, randomized, comparative trial of high-intensity focused ultrasound (HIFU) and low-dose-rate (LDR) brachytherapy in the treatment of localized prostate cancer are near to zero.
We should preface the following commentary by stating that there is no doubt that it takes time to learn to use high-intensity focused ultrasound (HIFU) really well as a form of first-line treatment for localized prostate cancer. This is hardly surprising.
A newly published paper from a clinical research group in Nice, France, has reported very limited data on a small cohort of patients with recurrent localized prostate cancer after first-line therapy who were given salvage therapy using various combinations of radiation therapy and high-intensity focused ultrasound (HIFU).
An article in the Sunday edition of the San Francisco Chronicle has raised questions about how physicians are reimbursed for carrying out high-intensity focused ultrasound (HIFU) procedures on prostate cancer patients in the Caribbean and Mexico.
According to a report posted yesterday on the Medscape web site, a Food and Drug Administration (FDA) advisory committee “voted October 1 not to recommend approval, at least for now” of a SonoCare Medical’s Sonablate high-intensity focused ultrasound (HIFU) device to treat patients with radio-recurrent
Over the weekend, one of our regular commentators brought to our attention a newly published, retrospective analysis of data on the risks and benefits of treatment of localized prostate cancer with three successive generations of high-intensity focused ultrasound (HIFU) equipment from the company now known as Sonocare Medical.
According to a report on the Bloomberg News web site, the FDA’s reviewers appear to be less than enthusiastic about the effectiveness and safety data submitted by EDAP TMS to support approval of the Ablatherm device for use of high-intensity focused ultrasound (HIFU) for the treatment of low-risk forms of prostate cancer.
According to a media release issued earlier today by EDAP TMS, the U.S. Food and Drug Administration (FDA) has scheduled a meeting on July 30, 2014, to review the Pre-Market Approval (PMA) application for EDAP’s Ablatherm-HIFU device for the treatment of localized prostate cancer.